Loxo Oncology, Inc. Income Statement | Understand Stock

Login

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Operations

In millions of USD; shares in millions, except per-share amounts

	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016	FY2015 12 months to Dec 31, 2015	FY2014 12 months to Dec 31, 2014
Revenue from collaboration agreement
Operating expenses:
Research and development with related party
Research and development
General and administrative
Total operating expenses and loss from operations
Total operating expenses
Loss from operations
Interest income, net
Net loss
Accretion of redeemable convertible preferred stock
Net loss attributable to common stockholders
Per share information:
Net loss per share of common stock-basic and diluted (in dollars per share)
Weighted-average shares outstanding-basic and diluted (in shares)

Loading...

Comments